Immunohistochemical expression of the glucose transporters Glut-1 and Glut-3 in human malignant melanomas and benign melanocytic lesions

Journal of Experimental and Clinical Cancer Research

Volumn 27, Issue 1, 2008, Pages

  Parente, Paola ^a   Coli, Antonella ^a   Massi, Guido ^a   Mangoni, Antonella ^a   Fabrizi, Manuela M ^a   Bigotti, Giulio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; TUMOR MARKER;

ARTICLE; CANCER CELL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JUVENILE MELANOMA; MELANOCYTIC NEVUS; MELANOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; METABOLISM; NEVUS; PATHOLOGY;

GLUCOSE TRANSPORTER TYPE 1; GLUCOSE TRANSPORTER TYPE 3; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; NEVUS, EPITHELIOID AND SPINDLE CELL; TUMOR MARKERS, BIOLOGICAL;

EID: 52949097303     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-27-34     Document Type: Article

References (34)

1. Structure, function, and regulation of the mammalian facilitative glucose transporter gene family. AL Olson JE Pessin, Annu Rev Nutr 1996 16 235 256 10.1146/annurev.nu.16.070196.001315 8839927
2. Coexpression of glucose transporter 1 and matrix metalloproteinase-2 in human cancers. S Ito T Fukusato T Nemoto H Sekihara Y Seyama S Kubota, J Natl Cancer Inst 2002 94 1080 1091 12122099
3. Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder. S Chang S Lee C Lee JI Kim Y Kim, Urol 2000 55 448 452 10.1016/S0090-4295(99)00474-4 10699635
4. A mouse model for Glut-1 haploinsufficiency. D Wang JM Pascual H Yang K Engelstad X Mao J Cheng J Yoo JL Noebels DC De Vivo, Hum Molecular Genet 2006 15 1169 1179 10.1093/hmg/ddl032
5. Role for glucose transporter 1 protein in human breast cancer. M Grover-McKay SA Walsh EA Seftor PA Thomas MJ Hendrix, Pathol Oncol Res 1998 4 115 120 9654596
6. Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity. H Ito M Duxbury MJ Zinner SW Ashley EE Whang, Surgery 2004 136 548 556 10.1016/j.surg.2004.05.032 15349101
7. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. R Airley J Loncaster S Davidson M Bromley S Roberts A Patterson R Hunter I Stratford C West, Clin Cancer Res 2001 7 4 928 934 11309343
8. GLUT-1 is preferentially expressed in atypical endometrial hyperplasia and endometrial adenocarcinoma. A Ashton-Sager AF Paulino AM Afify, Appl Immunohistochem Mol Morphol 2006 14 187 192 10.1097/01.pai.0000162003.43334.c7 16785788
9. Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. T Ito Y Noguchi S Satoh H Hayashi Y Inayama H Kitamura, Mod Pathol 1998 11 437 443 9619596
10. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Y Kato K Tsuta K Seki AM Maeshima S Watanabe K Suzuki H Asamura R Tsuchiya Y Matsuno, Mod Pathol 2007 20 215 220 10.1038/modpathol.3800732 17192790
11. Clinicopathological significance and linkage of the distribution of HIF-1alpha and GLUT-1 in human primary colorectal cancer. A Wincewicz M Sulkowska M Koda S Sulkowski, Pathol Oncol Res 2007 13 15 20 17387384
12. Glucose transporter-1 expression in the thyroid gland: clinicopathological significance for papillary carcinoma. M Yasuda N Ogane H Hayashi Y Kameda Y Miyagi T Iida Y Mori K Tsukinoki T Minematsu Y Osamura, Oncol Rep 2005 14 1499 1504 16273245
13. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography. U Tateishi U Yamaguchi K Seki T Terauchi Y Arai T Hasegawa, Eur J Nucl Med Mol Imaging 2006 33 683 691 10.1007/s00259-005-0044-8 16506050
14. Overexpression of GLUT-1 is associated with resistance to radiotherapy and adverse prognosis in squamous cell carcinoma of the oral cavity. M Kunkel M Moergel M Stockinger JH Jeong G Fritz HA Lehr TL Whiteside, Oral Oncol 2007 43 796 803 10.1016/j.oraloncology.2006.10.009 17207657
15. Glut1 expression in T1 and T2 stage colorectal carcinomas: its relationship to clinicopathological features. M Sakashita N Aoyama R Minami S Maekawa K Kuroda D Shirasaka T Ichihara Y Kuroda S Maeda M Kasuga, Eur J Cancer 2001 37 204 209 10.1016/S0959-8049(00)00371-3 11166147
16. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. RS Brown RL Wahl, Cancer 1993 72 2979 2985 10.1002/1097-0142(19931115)72:10<2979::AID-CNCR2820721020>3.0.CO;2-X 8221565
17. Differential gene expression profiling in human brain tumors. JM Markert CM Fuller GY Gillespie JK Bubien LA McLean RL Hong K Lee SR Gullans TB Mapstone DJ Benos, Physiol Genomics 2001 5 21 33 11161003
18. Expression of the human erythrocyte glucose transporter Glut1 in cutaneous neoplasia. SC Baer L Casaubon M Younes, J Am Acad Dermatol 1997 37 575 577 10.1016/S0190-9622(97)70174-9 9344196
19. Interleukin 1 stimulates hexose transport in fibroblasts by increasing the expression of glucose transporters. TA Bird A Davies SA Baldwin J Saklatvala, J Biol Chem 1990 265 13578 13583 2380175
20. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. T Higashi N Tamaki T Honda T Torizuka T Kimura T Inokuma G Ohshio R Hosotani M Imamura J Konishi, J Nucl Med 1997 38 1337 1344 9293783
21. Biological correlates of FDG uptake in non-small cell lung cancer. LF de Geus-Oei JH van Krieken RP Aliredjo PF Krabbe C Frielink AF Verhagen OC Boerman WJ Oyen, Lung Cancer 2007 55 79 87 10.1016/j.lungcan.2006.08.018 17046099
22. Mechanisms related to [18F]fluorodeoxyglucose uptake of human colon cancers transplanted in nude mice. JK Chung YJ Lee C Kim SR Choi M Kim K Lee JM Jeong DS Lee JJ Jang MC Lee, J Nucl Med 1999 40 339 346 10025844
23. 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. TC Yen LC See CH Lai CW Yah-Huei KK Ng SY Ma WJ Lin JT Chen WJ Chen CR Lai S Hsueh, J Nucl Med 2004 45 22 29 14734665
24. Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with 18F-2-fluoro-2-deoxy-D-glucose uptake by positron emission tomography in colorectal cancer. J Gu H Yamamoto H Fukunaga K Danno I Takemasa M Ikeda M Tatsumi M Sekimoto J Hatazawa T Nishimura M Monden, Dig Dis Sci 2006 51 2198 2205 10.1007/s10620-006-9428-2 17080242
25. Sentinel node biopsy in cutaneous melanoma: correlations between melanoma prognostic factors and sentinel node status. E Minutilli D Giannarelli M Anzà R Garinei P Perri C Botti L Piarulli P Bruno S Rea P Visca M Mottolese S Di Filippo F Di Filippo, J Exp Clin Cancer Res 2007 26 71 76 17550134
26. Variability in glucose transporter-1 levels and hexokinase activity in human melanoma. PR Wachsberger EL Gressen A Bhala SB Bobyock C Storck RA Coss D Berd DB Leeper, Melanoma Res 2002 12 35 43 10.1097/00008390-200202000-00006 11828256
27. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. JD Wagner D Schauwecker D Davidson JJ Coleman 3rd S Saxman G Hutchins C Love JT Hayes, J Clin Oncol 1999 17 1508 1515 10334538
28. Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II. AM Fink S Holle-Robatsch N Herzog S Mirzaei K Rappersberger N Lilgenau W Jurecka A Steiner, Melanoma Res 2004 14 141 145 10.1097/00008390-200404000-00011 15057045
29. Staging of regional nodes in AJCC stage I and II melanoma: 18FDG PET imaging versus sentinel node detection. T Belhocine G Pierard M De Labrassinne T Lahaye P Rigo, Oncologist 2002 7 271 278 10.1634/theoncologist.7-4-271 12185291
30. F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm. E Maubec J Lumbroso F Masson V Suciu F Kolb G Mamelle A Cavalcanti F Boitier A Spatz A Aupérin S Leboulleux MF Avril, Melanoma Res 2007 17 147 154 10.1097/CMR.0b013e32815c10b0 17505260
31. The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. CA Davies M Jeziorska AJ Freemont AL Herrick, Hum Pathol 2006 37 190 197 10.1016/j.humpath.2005.10.007 16426919
32. GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. RE Airley J Loncaster JA Raleigh AL Harris SE Davidson RD Hunter CM West IJ Stratford, Int J Cancer 2003 104 85 91 10.1002/ijc.10904 12532423
33. p300 and p53 levels determine activation of HIF-1 downstream targets in invasive breast cancer. MM Vleugel D Shvarts E van der Wall PJ van Diest, Hum Pathol 2006 37 1085 1092 10.1016/j.humpath.2006.03.015 16867872
34. Coordinate up-regulation of hypoxia inducible factor (HIF)-1α and HIF-1 target genes during multi-stage epidermal carcinogenesis and wound healing. DA Elson HE Ryan JW Snow R Johnson JM Arbeit, Cancer Res 2000 60 6189 6195 11085544